Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio per valutare l'efficacia e la sicurezza del bimekizumab nei soggetti con spondiloartrite assiale non radiografica attiva (BE MOBILE 1)

1 settembre 2026 aggiornato da: UCB Biopharma SRL

Uno studio di fase 3, multicentrico, randomizzato, in doppio cieco, controllato con placebo che valuta l'efficacia e la sicurezza di bimekizumab in soggetti con spondiloartrite assiale attiva non radiografica

The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active nonradiographic axial spondyloarthritis (nr-axSpA).

Panoramica dello studio

Stato

Completato

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

274

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Brussels, Belgio
        • As0010 40004
      • Genk, Belgio
        • As0010 40003
      • Ghent, Belgio
        • As0010 40001
      • Merksem, Belgio
        • As0010 40002
      • Plovdiv, Bulgaria
        • As0010 40006
      • Plovdiv, Bulgaria
        • As0010 40007
      • Sofia, Bulgaria
        • As0010 40005
      • Sofia, Bulgaria
        • As0010 40008
      • Brno, Cechia
        • As0010 40011
      • Pardubice, Cechia
        • As0010 40009
      • Prague, Cechia
        • As0010 40013
      • Prague, Cechia
        • As0010 40014
      • Prague, Cechia
        • As0010 40015
      • Prague, Cechia
        • As0010 40016
      • Uherské Hradiště, Cechia
        • As0010 40010
      • Zlín, Cechia
        • As0010 40012
      • Beijing, Cina
        • As0010 20040
      • Chengdu, Cina
        • As0010 20021
      • Guangzhou, Cina
        • As0010 20019
      • Hefei, Cina
        • As0010 20034
      • Nanjing, Cina
        • As0010 20024
      • Shanghai, Cina
        • As0010 20018
      • Shanghai, Cina
        • As0010 20020
      • Shanghai, Cina
        • As0010 20026
      • Wenzhou, Cina
        • As0010 20025
      • Boulogne-Billancourt, Francia
        • As0010 40018
      • Limoges, Francia
        • As0010 40022
      • Berlin, Germania
        • As0010 40025
      • Hamburg, Germania
        • As0010 40029
      • Hanover, Germania
        • As0010 40024
      • Herne, Germania
        • As0010 40027
      • Leipzig, Germania
        • As0010 40078
      • Ratingen, Germania
        • As0010 40026
      • Chūōku, Giappone
        • As0010 20030
      • Iruma-gun, Giappone
        • As0010 20039
      • Kawachi-Nagano, Giappone
        • As0010 20036
      • Kita-gun, Giappone
        • As0010 20045
      • Kitakyushu, Giappone
        • As0010 20065
      • Nankoku-shi, Giappone
        • As0010 20038
      • Osaka, Giappone
        • As0010 20037
      • Saga, Giappone
        • As0010 20084
      • Saitama, Giappone
        • As0010 20048
      • Sapporo, Giappone
        • As0010 20031
      • Tokyo, Giappone
        • As0010 20035
      • Elblag, Polonia
        • As0010 40038
      • Krakow, Polonia
        • As0010 40042
      • Lublin, Polonia
        • As0010 40037
      • Poznan, Polonia
        • As0010 40044
      • Torun, Polonia
        • As0010 40040
      • Warsaw, Polonia
        • As0010 40041
      • Wroclaw, Polonia
        • As0010 40039
      • Wroclaw, Polonia
        • As0010 40043
      • Edinburgh, Regno Unito
        • As0010 40057
      • Leeds, Regno Unito
        • As0010 40056
      • London, Regno Unito
        • As0010 40054
      • Norwich, Regno Unito
        • As0010 40055
      • A Coruña, Spagna
        • As0010 40045
      • Córdoba, Spagna
        • As0010 40046
      • Madrid, Spagna
        • As0010 40047
      • Santiago de Compostela, Spagna
        • As0010 40048
      • Seville, Spagna
        • As0010 40049
    • Arizona
      • Mesa, Arizona, Stati Uniti, 85210
        • As0010 50131
      • Phoenix, Arizona, Stati Uniti, 85032
        • As0010 50052
      • Sun City, Arizona, Stati Uniti, 85351
        • As0010 50062
    • California
      • Upland, California, Stati Uniti, 91786
        • As0010 50060
    • Florida
      • Ormond Beach, Florida, Stati Uniti, 32174
        • As0010 50059
      • Sarasota, Florida, Stati Uniti, 34239
        • As0010 50056
    • Maryland
      • Hagerstown, Maryland, Stati Uniti, 21740
        • As0010 50015
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63141
        • As0010 50016
    • Oregon
      • Portland, Oregon, Stati Uniti, 97239-3011
        • As0010 50055
    • Pennsylvania
      • Duncansville, Pennsylvania, Stati Uniti, 16635
        • As0010 50020
    • Tennessee
      • Memphis, Tennessee, Stati Uniti, 38119-5214
        • As0010 50012
    • Texas
      • Dallas, Texas, Stati Uniti, 75231
        • As0010 50057
      • Mesquite, Texas, Stati Uniti, 75150
        • As0010 50036
    • Washington
      • Spokane, Washington, Stati Uniti, 99204
        • As0010 50061
      • Ankara, Turchia (Türkiye)
        • As0010 40052
      • Ankara, Turchia (Türkiye)
        • As0010 40053
      • Istanbul, Turchia (Türkiye)
        • As0010 40050
      • Izmir, Turchia (Türkiye)
        • As0010 40051
      • Debrecen, Ungheria
        • As0010 40032
      • Szeged, Ungheria
        • As0010 40031
      • Szombathely, Ungheria
        • As0010 40080
      • Székesfehérvár, Ungheria
        • As0010 40033

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Male or female patients at least 18 years of age

  • Patient has nonradiographic axial spondyloarthritis (nr-axSpA) with all of the following criteria:

    1. Adult-onset axial spondyloarthritis meeting Assessment of SpondyloArthritis International Society (ASAS) classification criteria
    2. Inflammatory back pain for at least 3 months
    3. Age at symptom onset of less than 45 years
    4. NO sacroiliitis (in Anterior-Posterior pelvis or sacroiliac x-ray)
  • Active disease defined by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) >=4 AND spinal pain >=4 on a 0 to 10 Numeric Rating Scale

  • Objective inflammation defined by sacroiliitis on magnetic resonance imaging and/or elevated C-reactive protein

  • Subjects had to have either failed to respond to 2 different nonsteroidal anti-inflammatory drugs (NSAIDs) given at the maximum tolerated dose for a total of 4 weeks or have a history of intolerance to or a contraindication to NSAID therapy

  • Patients who have taken a tumor necrosis factor alpha (TNFα) inhibitor must have experienced an inadequate response or intolerance to treatment given at an approved dose for at least 12 weeks

  • Patients currently taking NSAIDs, cyclooxygenase 2 (COX-2) inhibitors, analgesics, corticosteroids, methotrexate (MTX), leflunomide (LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ) AND/OR apremilast can be allowed if they fulfill specific requirements prior to study entry

Exclusion Criteria:

  • Treatment with more than 1 TNFα inhibitor and/or more than 2 additional non-TNFα biological response modifiers, or any interleukin (IL)-17 biological response modifier
  • Active infection or history of recent serious infections
  • Viral hepatitis B or C or human immunodeficiency virus (HIV) infection
  • Any live (includes attenuated) vaccination within the 8 weeks prior to entering the study or TB (Bacillus Calmette-Guerin) vaccination within 1 year prior entering the study
  • Known tuberculosis (TB) infection, at high risk of acquiring TB infection, or current or history of nontuberculous mycobacterium (NTMB) infection
  • Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma or in situ cervical cancer
  • Diagnosis of inflammatory conditions other than axial spondyloarthritis (axSpA), including but not limited to psoriatic arthritis, rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus, and reactive arthritis. Patients with a diagnosis of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease (IBD) are allowed as long as they have no active symptomatic disease when entering the study
  • Presence of active suicidal ideation, or moderately severe major depression or severe major depression
  • Female patients who are breastfeeding, pregnant, or planning to become pregnant during the study
  • Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Bimekizumab

Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.

Subjects will receive bimekizumab at pre-specified time-points.

Altri nomi:
  • UCB4940
  • BKZ
Comparatore placebo: Placebo

Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.

Subjects will receive bimekizumab at pre-specified time-points.

Altri nomi:
  • UCB4940
  • BKZ

Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.

Altri nomi:
  • PBO

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16
Lasso di tempo: Week 16

ASAS40 response is defined as relative improvements of at least 40% and absolute improvement of at least 2 units in at least 3 of the 4 following components:1) Patient's Global Assessment of Disease Activity (PGADA) assessed on a scale ranging from 0 [not active] to 10 [very active], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 [no pain] to 10 [most severe pain], higher score= higher pain intensity, 3) Bath Ankylosing Spondylitis Functional Index (BASFI) assessing participant's level of ability on a scale ranging from 0 [easy] to 10 [impossible] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), each assessed on a scale ranging from 0 [none / 0 hour] to 10 [very severe / 2 or more hours], higher score=higher severity; and no worsening at all in the remaining component.

Week 16

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response in TNFα Inhibitor-naïve Subjects at Week 16
Lasso di tempo: Week 16

ASAS40 response is defined as relative improvements of at least 40% and absolute improvement of at least 2 units in at least 3 of the 4 following components:1) Patient's Global Assessment of Disease Activity (PGADA) assessed on a scale ranging from 0 [not active] to 10 [very active], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 [no pain] to 10 [most severe pain], higher score= higher pain intensity, 3) Bath Ankylosing Spondylitis Functional Index (BASFI) assessing participant's level of ability on a scale ranging from 0 [easy] to 10 [impossible] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), each assessed on a scale ranging from 0 [none / 0 hour] to 10 [very severe / 2 or more hours], higher score=higher severity; and no worsening at all in the remaining component.

Week 16
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Week 16
Lasso di tempo: Baseline, Week 16

BASDAI is a well-established patient-reported endpoint assessing severity of AS symptoms. It is made of 6 items assessing severity of fatigue, spinal pain, peripheral joint pain & swelling, enthesitis, & morning stiffness (both severity and duration). Each question is rated using a numerical rating scale ranging from 0 (none) to 10 (very severe), higher score=higher symptom severity.BASDAI score is calculated by computing mean of questions 5 and 6 & adding it to sum of questions 1 to 4.This score is then divided by 5.Total BASDAI score ranges from 0=no disease activity to 10=maximal disease activity, higher score indicates higher symptom severity. A negative change reflects improvement.

Baseline, Week 16
Percentage of Participants With Assessment of SpondyloArthritis International Society 20% Response Criteria (ASAS20) Response at Week 16
Lasso di tempo: Week 16

ASAS20 response is defined as relative improvements of at least 20% and absolute improvement of at least 1 unit in at least 3 of the 4 following components:1) PGADA assessed on a scale ranging from 0 [not active] to 10 [very active], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 [no pain] to 10 [most severe pain], higher score= higher pain intensity, 3) BASFI assessing participant's level of ability on a scale ranging from 0 [easy] to 10 [impossible] on 10 physical activities, 4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI, each assessed on a scale ranging from 0 [none / 0 hour] to 10 [very severe / 2 or more hours], higher score=higher severity; and no worsening at all in the remaining component.

Week 16
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) Partial Remission (PR) at Week 16
Lasso di tempo: Week 16

The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of less than or equal to (<=) 2 units in each of the 4 following components:1) PGADA assessed on a scale ranging from 0 [not active] to 10 [very active], higher score=higher disease activity,2) Spinal Pain assessed on a scale ranging from 0 [no pain] to 10 [most severe pain], higher score= higher pain intensity, 3) BASFI assessing participant's level of ability on a scale ranging from 0 [easy] to 10 [impossible] on 10 physical activities, and 4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI scale, each assessed on a scale ranging from 0 [none / 0 hour] to 10 [very severe / 2 or more hours], higher score=higher severity.

Week 16
Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) at Week 16
Lasso di tempo: Week 16

ASDAS-MI is achieved when there is a reduction (improvement) greater or equal to (>=) 2.0 in ASDAS relative to Baseline. ASDAS is calculated by adding the 5 following components: 1) 0.121 × Neck, back or hip pain (BASDAI Q2), 2) 0.058 × Duration of morning stiffness (BASDAI Q6), 3) 0.110 × Patient's Global Assessment of Disease Activity (PGADA), 4) 0.073 × Peripheral pain/swelling in joints (BASDAI Q3), 5) 0.579 × (natural logarithm of the C-reactive protein (CRP) [mg/L] + 1). Q2, Q3 and Q6 from BASDAI and PGADA, are all assessed on a numerical scale from 0 [none / not active] to 10 [very severe / very active]. There is a minimum score of 0.980 for ASDAS (as a fixed value of 2 is assumed for values of hs-CRP below the lower limit of quantification (LLOQ)), but no defined upper score. Higher ASDAS scores reflect higher disease activity and participants achieving ASDAS-MI are considered to have a major improvement in their disease.

Week 16
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response at Week 16
Lasso di tempo: Week 16

ASAS 5/6 response is defined as achieving at least 20% improvement in 5 of the following 6 components:1) PGADA assessed on a scale ranging from 0 [not active] to 10 [very active], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 [no pain] to 10 [most intense pain], higher score=higher pain intensity,3) BASFI assessing participant's level of ability on a scale ranging from 0 [easy] to 10 [impossible] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI scale, each assessed on a scale ranging from 0 [none/ 0 hour] to 10 [very severe / 2 or more hours], higher score=higher severity;5) spinal mobility (ie, lateral spinal flexion component of Bath Ankylosing Spondylitis Disease Metrology Index) on a scale ranging from 0 [no limitation of movement] to 10 [very severe limitation of movement] and 6) high sensitivity C-reactive protein (hs-CRP).

Week 16
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16
Lasso di tempo: Baseline, Week 16

The BASFI is a well-established PRO measure of physical functioning used in AxSpA trials. It assesses participants' level of ability during the past week in conducting 10 physical activities on a scale ranging from 0 [easy] to 10 [impossible]. The BASFI score is the mean of the 10 item scores and ranges from 0 to 10, with lower scores indicating better physical function. A negative change in BASFI indicates improvement. The higher the negative value the better the improvement.

Baseline, Week 16
Change From Baseline in Nocturnal Spinal Pain Score Using Numeric Rating Scale (NRS) at Week 16
Lasso di tempo: Baseline, Week 16

Nocturnal spinal pain experienced by participants with axial spondyloarthritis (axSpA) was assessed on a numerical rating scale ranging from 0 (no pain) to 10 (most severe pain). A lower score indicates less pain and a negative change represents an improvement.

Baseline, Week 16
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Total Score at Week 16
Lasso di tempo: Baseline, Week 16

The Ankylosing Spondylitis Quality of Life (ASQoL) is an 18-item PRO measure developed specifically for measuring health-related quality of life (HRQoL) in participants with ankylosing spondylitis and validated in the full spectrum of axial spondyloarthritis (axSpA). Each item is given a score of 1 for positive responses indicating impaired quality of life, and a score of 0 for negative responses. All item scores are summed to generate the total score ranging from 0 to 18 with a higher score indicating worse HRQoL. A negative change represents an improvement.

Baseline, Week 16
Change From Baseline in the Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 16
Lasso di tempo: Baseline, Week 16

SF-36 is a 36-item HRQoL instrument with recall period of 4 weeks. Items are grouped into 8 domains: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items) and 1 item for Health Transition during last year. PCS and Mental Component Summary (MCS) scores are calculated from 8 domains (excluding Health Transition item). Each of SF-36 derived raw scores range from 0 to 100; higher score = better function. PCS score is calculated from 8 domain scores. It is standardized score ranging from 7.3 to 70.1, with a mean of 50 and SD of 10 in general US population, higher values = better function, and positive change reflects improvement. A PCS score mean below 47 indicates impaired physical functioning. Individual respondent's score that falls outside T-score range of 45 to 55 are outside average general US population range.

Baseline, Week 16
Change From Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16
Lasso di tempo: Baseline, Week 16

The BASMI characterizes the spinal mobility of participants with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis. It is a disease-specific measure consisting of 5 clinical measures to reflect participant axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 was calculated for each item based on the measurement. The mean of the 5 scores provides the total BASMI score (ranging from 0 to 10). The higher the BASMI score, the more severe the participant's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value, the better the improvement.

Baseline, Week 16
Change From Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline at Week 16
Lasso di tempo: Baseline, Week 16

The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score reflects higher severity and a negative change represents an improvement.

Baseline, Week 16
Percentage of Participants With Enthesitis-free State at Week 16 Based on the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline
Lasso di tempo: Baseline, Week 16

The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. Enthesitis free state is defined as having a MASES score of 0. A higher score reflects higher severity and a negative change represents an improvement.

Baseline, Week 16
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
Lasso di tempo: From Baseline (Day 1) until Safety-Follow-Up (up to Week 68) (Week 48 last IMP intake + 20 weeks SFU)

TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety follow up (SFU)). TEAEs were analyzed and have been reported separately for Double-Blind Treatment Period (Safety set),Maintenance Period (MP) (Maintenance Set) and Overall Period (Safety set) which includes all participants who received BKZ 160 mg Q4W during the study. The overall period arm reports repeated TEAEs from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, Maintenance Period (MP) included AEs of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.

From Baseline (Day 1) until Safety-Follow-Up (up to Week 68) (Week 48 last IMP intake + 20 weeks SFU)
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study
Lasso di tempo: From Baseline (Day 1) until Safety Follow-Up (up to Week 68)

A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulted in 1) Death, 2) Life-threatening (Life-threatening does not include a reaction that might have caused death had it occurred in a more severe form.), 3) Significant or persistent disability/incapacity, 4) Congenital anomaly/birth defect (including that occurring in a fetus), 5) Important medical event that, based upon appropriate medical judgment, may jeopardize the participant or participant may require medical or surgical intervention to prevent any of the above, 6) Initial inpatient hospitalization or prolongation of hospitalization. The overall period arm reports repeated SAEs from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, MP included SAEs of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.

From Baseline (Day 1) until Safety Follow-Up (up to Week 68)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study
Lasso di tempo: From Baseline (Day 1) until Safety-Follow-Up (up to Week 68)

TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). The overall period arm reports repeated events from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, MP included events of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.

From Baseline (Day 1) until Safety-Follow-Up (up to Week 68)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: UCB Cares, 001 844 599 2273

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

25 aprile 2019

Completamento primario (Effettivo)

29 giugno 2022

Completamento dello studio (Effettivo)

17 aprile 2023

Date di iscrizione allo studio

Primo inviato

23 aprile 2019

Primo inviato che soddisfa i criteri di controllo qualità

25 aprile 2019

Primo Inserito (Effettivo)

26 aprile 2019

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

25 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

1 settembre 2026

Ultimo verificato

1 agosto 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Periodo di condivisione IPD

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Criteri di accesso alla condivisione IPD

Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi